German patent court publishes reasoning in Gilead SPC dispute

Germany’s Federal Patent Court (Bundespatentgericht, BpatG) has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate (SPC) for HIV/AIDS treatment Truvada,

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Gilead announces licence and collaboration deal with Yuhan

10 January 2019 Gilead Sciences, a biopharmaceutical company based in the US, has entered into a licensing and collaboration agreement with South Korean healthcare company Yuhan.

Big Pharma

CJEU clarifies ‘basic patent’ meaning in SPC dispute

25 July 2018 Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.

Big Pharma

French court knocks out Gilead Truvada SPC

4 June 2018 The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.